OncLive TV

Rebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.

R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.

R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.

Mario Sznol, MD, discusses current guidance around the use of neoadjuvant therapy in advanced melanoma.

Lore Gruenbaum, PhD, discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma.

Mario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data.

Michael Mauro, MD, details the FDA approval of the small-molecule formulation of dasatinib and other alternate TKI formulations in chronic myeloid leukemia.

Alexander B. Olawaiye, MD, discusses the clinical significance of the FDA approval of relacorilant plus nab-paclitaxel in PROC.

Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.

Jonathan Wennan Lee, MD, MSc, discusses future directions for studying PD-L1 as a predictive biomarker in EGFR-mutated NSCLC.

Ajai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.

Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.

Mario Sznol, MD, discusses the uncertainties around predicting benefit with immune checkpoint inhibitors in metastatic melanoma.

Shubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.

Deirdre J. Cohen, MD, MS, discusses clinical decision-making and the comparative efficacy of FOLFIRINOX and NALIRIFOX in metastatic pancreatic cancer.

Shubham Pant, MD, MBBS, discusses the management of dermatologic and GI toxicities associated with the RAS(ON) inhibitor daraxonrasib.

Bradley McGregor, MD, discusses the end points that will be evaluated in the phase 3 STRIKE trial of adjuvant tivozanib plus pembrolizumab in high-risk RCC.

Andrew Kuykendall, MD, explains considerations for JAK inhibitor sequencing and the use of transplant in myelofibrosis.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the potential future utility of PD-L1 expression as a biomarker in EGFR-mutated NSCLC.

Mario Sznol, MD, discusses long-term melanoma survival, treatment gaps after progression, and emerging strategies for resistant disease.

Neil D. Gross, MD, FACS, discusses the importance of year-round vigilance when it comes to skin cancer prevention and education.

Bradley McGregor, MD, discusses the rationale of the STRIKE trial of tivozanib plus pembrolizumab in RCC.

Shubham Pant, MD, MBBS, discusses results from the landmark phase 3 RASolute 302 trial for daraxonrasib in previously treated metastatic PDAC.

Alexey Danilov, MD, PhD, discusses second-line treatment selection for patients with chronic lymphocytic leukemia who have received venetoclax-based regimens.

Mario Sznol, MD, discusses the current therapeutic landscape in the frontline setting for patients with advanced or metastatic melanoma.

Ashley Sumrall, MD, FACP, FASCO, discusses CAR T-cell therapies and BTK inhibitors in primary central nervous system lymphoma and the role they play.

Bradley Monk, MD, FACOG, FACS, discusses the relevance of FRα, HER2, and PD-L1 expression in influencing decision-making in recurrent ovarian cancer.

Mina M. Fam, MD, and Bradley McGregor, MD, discuss the treatment landscape of testicular cancer during Testicular Cancer Awareness Month.

Timothy N. Clinton, MD, discusses initiatives to improve outcomes for female patients with bladder cancer.

Vinayak Venkataraman, MD, discusses how certain biological requirements for emerging cellular therapies could exacerbate racial disparities in sarcoma.